Loading patent…
OwnerJean-Pol Cassart, Catherine Gerard +2inventors
InventorsJean-Pol Cassart, Catherine Gerard, Paul Hamblin, Remi Palmantier
Estimating the term…
The present invention relates to pharmaceutical/immunogenic compositions and methods for inducing an immune response against tumour-related antigens. More specifically, the invention relates to non-human prostate-specific antigens, more precisely to the non-human prostate-specific P501S, which can be used as xenogeneic antigen in prostate cancer vaccine therapy and as diagnostic agents for prostate tumours in humans, to immunogenic compositions containing them, to methods of manufacture of such compositions and to their use in medicine. Methods for formulating vaccines for immunotherapeutically treating P501S-expressing prostate tumors, prostatic hyperplasia, and prostate intraepithelilial neoplasia (PIN) are also provided.
An immunogenic composition comprising a xenogeneic P501S polypeptide or a xenogeneic P501S-encoding polynucleotide, or an immunogenic fragment thereof;
An immunogenic composition comprising an effective amount of antigen presenting cells, modified by in vitro loading with a xenogeneic P501S polypeptide or immunogenic fragment thereof, or genetically modified in vitro to express a xenogeneic P501S polypeptide and a pharmaceutically effective carrier.
An isolated polypeptide comprising an amino acid sequence which has at least 92% identity to the amino acid sequence of SEQ ID NO:1 over the entire length of SEQ ID NO:1.
The isolated polypeptide of SEQ ID NO:1.
An isolated polynucleotide comprising a nucleotide sequence encoding a polypeptide that has at least 92% identity to the amino acid sequence of SEQ ID NO:2, over the entire length of SEQ ID NO:2;
A method of inducing an immune response against human P501S having an amino acid sequence as set forth in SEQ ID NO:5 to SEQ ID NO:7 in a human, comprising administering to the subject an effective dosage of an immunogenic composition comprising a xenogeneic form of said human P501S.
Dependencies are inferred from the claim text.